ACCEPTABILITY AND CLINICAL ACTIVITY OF 4 WEEKS TREATMENT BY S12024-2 IN 53 INPATIENTS WITH MODERATE TO SEVERE ALZHEIMERS-DISEASE

被引：0
|
作者：
ALLAIN, H
WEANES, K
NEUMAN, E
GANDON, JM
SALZMAN, V
MALBEZIN, M
GUEZ, D
机构：
[1] INST RECH INT SERVIER,F-92415 COURBEVOIE,FRANCE
[2] CDR LTD,READING R07 2BJ,BERKS,ENGLAND
[3] BIOTRIAL SA,DRUG EVALUAT & PHARMACOL RES,F-35000 RENNES,FRANCE
来源：
NEUROBIOLOGY OF AGING | 1994年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S136 / S137
页数：2
相关论文
共 50 条
  • [41] Impact of CYP2D6 and CYP3A4 Genetic Polymorphism on Combined Cholinesterase Inhibitors and Memantine Treatment in Mild to Moderate Alzheimer's Disease
    Sonali, Nirmal
    Tripathi, Manjari
    Sagar, Rajesh
    Velpandian, Thirumurthy
    Subbiah, Vivekanandhan
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2014, 37 (1-2) : 58 - 70
  • [42] POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMERS-DISEASE - SYNTHESIS AND BIOLOGICAL-ACTIVITY OF CARBAMATES, AMIDES AND UREAS OF (+/-)-5-AMINO-CIS-1,2,3,3A,8,8A-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO[2,3-B]INDOLE
    OMALLEY, GJ
    MERRIMAN, M
    WHITE, J
    CORNFELDT, M
    HUGER, F
    ALLEN, RC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 200 : 21 - MEDI
  • [43] IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trial
    Kimball, A. B.
    Krueger, J.
    Sullivan, T.
    Arbeit, R. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S26 - S26
  • [44] Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
    Shen, Nan
    Ignatenko, Stanislav
    Gordienko, Alexander
    Cortes Hernandez, Josefina
    Agmon-Levin, Nancy
    Narongroeknawin, Pongthorn
    Romanowska-Prochnicka, Katarzyna
    Ciferska, Hana
    Kodera, Masanari
    Wei, James Cheng-Chung
    Leszczynski, Piotr
    Lan, Joung-Liang
    Mysler, Eduardo
    Wojciechowski, Rafal
    Tarr, Tunde
    Vishneva, Elena
    Chen, Yi-Hsing
    Kaneko, Yuko
    Finzel, Stephanie
    Hoi, Alberta
    Koolvisoot, Ajchara
    Lee, Shin-Seok
    Dai, Lie
    Kaneko, Hiroshi
    Rojkovich, Bernadette
    Sun, Lingyun
    Zotkin, Eugeny
    Viallard, Jean-Francois
    Katayama, Masao
    Magallares-Lopez, Berta Paula
    Sengupta, Tirtha
    Sips, Carol
    Oliver, Stephen J.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4936 - 4939
  • [45] Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study
    Sands, B. E.
    Colombel, J. F.
    Rubin, D. T.
    Schreiber, S.
    Siegel, C. A.
    Yarur, A.
    Danese, S.
    Kang, A.
    Kim, D. H.
    Lee, Y. N.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1254 - I1256
  • [46] Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
    Laakso, Markku
    Rosenstock, Julio
    Groop, Per-Henrik
    Barnett, Anthony H.
    Gallwitz, Baptist
    Hehnke, Uwe
    Tamminen, Ilkka
    Patel, Sanjay
    von Eynatten, Maximilian
    Woerle, Hans-Juergen
    DIABETES CARE, 2015, 38 (02) : E15 - E17
  • [47] Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
    Seong-Ho Koh
    Hyuk Sung Kwon
    Seong Hye Choi
    Jee Hyang Jeong
    Hae Ri Na
    Chan Nyoung Lee
    YoungSoon Yang
    Ae Young Lee
    Jae-Hong Lee
    Kyung Won Park
    Hyun Jeong Han
    Byeong C. Kim
    Jin Se Park
    Jee-Young Lee
    Sangjae Kim
    Kyu-Yong Lee
    Alzheimer's Research & Therapy, 13
  • [48] Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
    Vermeire, S.
    Schreiber, S.
    Petryka, R.
    Kuehbacher, T.
    Hebuterne, X.
    Roblin, X.
    Klopocka, M.
    Goldis, A.
    Wisniewska-Jarosinska, M.
    Baranovsky, A.
    Sike, R.
    Stoyanova, K.
    Meuleners, L.
    Tasset, C.
    Van der Aa, A.
    Harrison, P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S13 - S14
  • [49] MAINTENANCE OF CLINICAL EFFECT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE TREATED WITH FILGOTINIB, A SELECTIVE JAK1 INHIBITOR: EXPLORATORY 20-WEEK DATA ANALYSIS OF THE PHASE 2 FITZROY STUDY
    Vermeire, Severine
    Schreiber, Stefan
    Petryka, Robert
    Kuehbacher, Tanja
    Hebuterne, Xavier
    Roblin, Xavier
    Klopocka, Maria
    Goldis, Adrian
    Wisniewska-Jarosinska, Maria A.
    Baranovsky, Andrei
    Sike, Robert
    Stoyanova, Kremena
    Meuleners, Luc
    Tasset, Chantal T.
    Van der Aa, Annegret
    Harrison, Pille
    GASTROENTEROLOGY, 2017, 152 (05) : S601 - S601
  • [50] Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
    Koh, Seong-Ho
    Kwon, Hyuk Sung
    Choi, Seong Hye
    Jeong, Jee Hyang
    Na, Hae Ri
    Lee, Chan Nyoung
    Yang, YoungSoon
    Lee, Ae Young
    Lee, Jae-Hong
    Park, Kyung Won
    Han, Hyun Jeong
    Kim, Byeong C.
    Park, Jin Se
    Lee, Jee-Young
    Kim, Sangjae
    Lee, Kyu-Yong
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
12345